Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus NOXAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus NOXAFIL.
DIFLUCAN vs NOXAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
Posaconazole oral suspension: 200 mg (5 mL) three times daily with food. Oral delayed-release tablets: 300 mg twice daily on day 1, then 300 mg once daily thereafter with food. IV: 300 mg twice daily on day 1, then 300 mg once daily.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal elimination half-life is approximately 25-30 hours (range 20-66 hours) in healthy subjects; in patients with hepatic impairment or critical illness, half-life may be prolonged up to 40-50 hours; supports once-daily dosing in most patients.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily hepatic metabolism (glucuronidation) with extensive enterohepatic recirculation; renal excretion accounts for <1% as unchanged drug; approximately 71% of a radiolabeled dose is eliminated in feces (as parent drug and metabolites) and 13% in urine (as metabolites).
Category C
Category C
Antifungal
Antifungal